PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung

#2198

Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.

Aim(s): We aimed to clarify PD-L1 expression status and its prognostic significance in lung neuroendocrine tumors.

Materials and methods: Tumor-associated inflammation was evaluated in 57 resected carcinoids and in 185 resected neuroendocrine carcinomas (NECs) of the lung (58 large cell and 127 small cell type). Immunohistochemical PD-L1 (clone 22C3) expression was separately assessed in immune cells (IC) and tumor cells (TC). CD8 and CD68 were evaluated in representative cases. All data were correlated with follow up.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Atsuko K

Authors: Kasajima A, Ishikawa Y, Iwata A, Steiger K, Oka N,

Keywords: Lung NEN, PD-L1, Prognosis,